Clinical trial · Interventional
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
A Phase I Open-labeled, Dose-escalation, Safety Study of the Combination of Velcade and Chemoradiation for the Treatment of Cancer Patients
NCT00329589CI-TRIAL-00089227completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety of Velcade when used with chemoradiation in cancer patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Cancer | Malignant Brain Neoplasm | ALIAS | 0.90 |
| Central Nervous System Neoplasms | Central Nervous System Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Cervix Cancer | — | UNRESOLVED | — |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Velcade (bortezomib) | Drug | Bortezomib | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- CNS
- description
- Velcade (bortezomib)
- interventionNames
- Drug: Velcade (bortezomib)
- type
- EXPERIMENTAL
- label
- Head and Neck
- description
- Velcade (bortezomib)
- interventionNames
- Drug: Velcade (bortezomib)
- type
- EXPERIMENTAL
- label
- Cervix
- description
- Velcade (bortezomib)
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed malignancy * Requiring at least grade 2 weeks of radiation therapy * Solid tumors of the central nervous system, head and neck area, and cervix * World Health Organization (WHO) performance status equal to or less than 2 Exclusion Criteria: * Equal to or greater than grade 2 peripheral neuropathy * Myocardial infarction within 6 months * Hypersensitivity to bortezomib, boron, or mannitol
References
Publications (0)
Data not yet available
No reference posted for this study.